Drug interactions

The study of the effect of the drug on metabolizing enzymes and relevant transporters is required in the assessment of drug interactions potential of new compounds.

In the case a new compound inhibits or induces  enzymes involved in metabolism, such as the family of cytochromes P450 (CYP), the pharmacokinetics and/or the pharmacodynamics of a concomitant medication can be affected, leading to reduced efficacy or, on the contrary, to an exaggerated pharmacological effect or drug toxicity. This assessment is based on an in vitro evaluation of CYP inhibition in both, as reversible inhibition as well as time-dependent inhibition, and on an evaluation of CYP induction.

Interactions with transporters can also alter a concomitant drug’s disposition and, consequently, its pharmacological action. The inhibition of key efflux transporters involved in drug interactions with drugs in clinical use, such as P-gp and BCRP, should be studied.

Based on the in vitro data obtained in the mentioned studies, along with the estimated relevant concentration in vivo, the need of further in vivo evaluation can be assessed.

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS